scPharmaceuticals reports positive results for low volume, pH neutral furosemide formulation SCP-111, demonstrating similar bioavailability and pharmacokinetics to IV furosemide in a study.

scPharmaceuticals reports positive topline results for its investigational low volume, pH neutral furosemide formulation, SCP-111, administered via an autoinjector. The results demonstrated similar bioavailability and pharmacokinetics compared to IV furosemide in a single-dose, randomized, two-way crossover study. The company plans to submit a Supplemental New Drug Application (sNDA) to the FDA by year-end 2024, targeting treatment flexibility for cardiologists and heart failure specialists.

August 12, 2024
3 Articles

Further Reading